Specific Peptides

Is sermorelin affected by the FDA's peptide restrictions?

Sermorelin was not among the twelve substances the FDA removed from Category 2 of its interim 503A bulk substances list in April 2026, so it sits in a different regulatory position from BPC-157, TB-500, KPV, MOTS-c, epithalon and DSIP. That is not the same as being approved: sermorelin's branded product was discontinued in 2008, and the sermorelin available today is a compounded preparation, which is not FDA-approved and is not reviewed by the FDA for safety or effectiveness. Peptide regulation moved more than once during 2026, and ACT 2 Health states the status on each peptide's own page rather than describing the category as settled.

Sermorelin ODT

What is sermorelin used for?

Sermorelin is prescribed to support the body's own release of growth hormone in adults whose evaluation and labs point to a declining growth hormone axis, with sleep quality, recovery, energy and body composition the outcomes usually watched. None of those is a promised result, and compounded sermorelin is not FDA-approved for any of them. What makes it worth a monitored trial where it is appropriate is that the response is measurable: IGF-1 shows whether the axis responded at all.

Sermorelin: a closer look

Is sermorelin safe?

Sermorelin's safety in any individual rests on screening, monitoring and sourcing rather than on the molecule alone, and the compounded form is not FDA-approved or reviewed by the FDA for safety. Because it prompts your pituitary to release its own growth hormone rather than supplying hormone from outside, your existing feedback control stays in place — an argument from physiology rather than from long-term outcome trials, which do not exist for it. Active cancer is an exclusion, and IGF-1 is checked before starting and during treatment.

Sermorelin ODT

Does sermorelin cause cancer?

No study has shown that sermorelin causes cancer, and no study has been large enough or long enough to show that it does not — both halves of that sentence are true, and neither should be dropped. The concern is indirect: sermorelin raises IGF-1, and higher IGF-1 is associated with a modestly increased risk of certain cancers at a population level, which is an association rather than a demonstrated effect of this treatment. ACT 2 Health screens for cancer history before prescribing and monitors IGF-1 rather than treating the question as closed.

Sermorelin and cancer risk

Can I take sermorelin if I have had cancer?

Active cancer is an absolute exclusion for sermorelin at ACT 2 Health, and no evaluation gets around it. A past cancer is a decision that belongs with your oncologist rather than with a telehealth prescriber alone, and for hormone-responsive cancers the default answer is no. Treatment aimed at the growth hormone axis is one of the clearest cases where the correct clinical answer is often to decline.

Sermorelin and cancer risk

Is sermorelin safer than growth hormone?

Sermorelin is expected to be safer than injected growth hormone because it acts one step upstream — prompting a pulsatile release your own feedback loops still regulate, instead of imposing continuous high hormone levels from outside — but that expectation has never been tested in outcome studies comparing the two. An argument from physiology is a reasonable basis for preferring an approach; it is not evidence that the risk is lower. Compounded sermorelin is also not FDA-approved, while growth hormone is an approved drug restricted to specific diagnoses.

Sermorelin and cancer risk

Does sermorelin help you sleep?

Sermorelin may support deep, slow-wave sleep, because growth-hormone-releasing hormone — the signal sermorelin mimics — both triggers growth hormone release and promotes slow-wave sleep, and studies of that signal in older adults reported modest increases in deep sleep. That is a reasonable mechanism with small supporting evidence behind it, not a treatment: sermorelin is not FDA-approved for insomnia or any sleep disorder. Poor sleep with a findable cause should be assessed first, which is covered in sleep.

Sermorelin and sleep

Will sermorelin help with sleep apnea?

No. Obstructive sleep apnea is a mechanical airway problem, it is diagnosed with a sleep study, and it has its own treatments — none of which is a peptide. ACT 2 Health screens for apnea symptoms before prescribing sermorelin, because untreated apnea is one of the most common reasons midlife fatigue and poor recovery fail to respond to anything else. Treating suspected apnea with a peptide mainly delays the diagnosis that would help.

Sermorelin and sleep

Does sermorelin raise IGF-1?

In a person whose pituitary can respond, yes — and that rise is the reason IGF-1 is measured. IGF-1 is the marker showing that the growth hormone axis responded and, with an oral dissolving tablet, that the medication was absorbed at all; no movement over an adequate period is a reason to reconsider rather than to persist. It is also the marker that keeps the safety conversation honest, since IGF-1 is what connects this treatment to the cancer-risk question.

IGF-1 on sermorelin

How often is IGF-1 checked on sermorelin?

IGF-1 is checked before starting, again at the first review once treatment has had time to show an effect, and periodically for as long as sermorelin continues. The baseline matters as much as the follow-up: without it, a later result cannot tell you whether anything changed. Monitoring that stops after the first few weeks is a sign the program is selling a subscription rather than treating you.

IGF-1 on sermorelin

Is BPC-157 FDA-approved?

No. BPC-157 is not an FDA-approved drug for any indication, and it is not on the FDA's 503A Bulks List that governs which substances a pharmacy may compound. An advisory committee recommended adding it in July 2026, but that is advice to the agency rather than a decision: formal addition requires notice-and-comment rulemaking, which had not completed as of September 2026. Compounded preparations are not FDA-approved and are not reviewed by the FDA for safety or effectiveness.

BPC-157: regulatory status

Is BPC-157 legal?

BPC-157's regulatory status is unsettled rather than clearly legal or clearly banned, and anyone describing it as either is ahead of the facts. It is not an approved drug and it is not on the 503A Bulks List; an FDA advisory committee recommended it for that list in July 2026, and the rulemaking that would complete the change had not finished as of September 2026. Material sold online as BPC-157 is usually labeled research use only, which is a laboratory chemical rather than a medicine — and this is a description of regulatory status, not legal advice.

BPC-157: regulatory status

Can a pharmacy compound BPC-157 right now?

Not on the strength of what happened in 2026. Neither the April 2026 removal from Category 2 of the interim list nor the July 2026 advisory committee vote placed BPC-157 on the 503A Bulks List, and that listing is what the compounding framework turns on. The rulemaking that would settle it had not completed as of September 2026, which is why ACT 2 Health states the position on the page rather than describing the question as resolved.

BPC-157: regulatory status

Why is BPC-157 sold everywhere if it is not approved?

Because most of what is sold is offered as a research chemical rather than as a medicine, which puts it outside the framework governing drugs altogether. A product labeled research use only carries no assurance of identity, purity, sterility or content, and nobody in that supply chain is accountable for what the vial holds. Wide availability reflects a gap in labeling and enforcement, not a verdict on whether BPC-157 is safe or works.

BPC-157: regulatory status

Is the BPC-157 sold online the same as a prescription?

No. BPC-157 sold online is typically labeled for research use only, meaning no pharmacist prepared it, no prescriber authorized it, and nobody verified its identity, purity or content — testing of peptides bought that way has repeatedly found products that were not what the label said. A prescription means a clinician licensed in your state evaluated you and a named, licensed compounding pharmacy prepared the medication for you specifically. ACT 2 Health does not help anyone obtain peptides outside a prescription.

BPC-157

Does BPC-157 work?

Nobody knows yet, and that is the honest state of the evidence. In rodent injury models BPC-157 consistently outperforms no treatment, which is why the compound is discussed at all; in humans it has never been tested for the uses it is best known for, and BPC-157 is not FDA-approved. A preclinical result is a reason to run a trial rather than a substitute for having run one.

BPC-157: the evidence

Are there human studies of BPC-157?

A small number, from a drug development program in the late 1990s and 2000s aimed at inflammatory bowel disease — early-phase, small, and largely reported in abstract form rather than as full published trials. No published human trial covers tendon, muscle or joint healing, which is what BPC-157 is now mostly marketed for. That gap between what was studied and what is claimed is the most important thing to understand about this compound.

BPC-157: the evidence

Is BPC-157 safe?

Short-term human exposure in those early trials did not raise safety concerns and animal work has not shown toxicity, but long-term safety in people has never been studied, and an absence of data is not a finding of safety. BPC-157 is not FDA-approved, so there is no labeled risk profile of the kind an approved medicine carries. Sourcing belongs inside the safety question too: a vial of unverified identity and purity carries risks that have nothing to do with the molecule.

BPC-157: the evidence

Is BPC-157 good for leaky gut?

No human trial has shown that BPC-157 improves intestinal permeability, and leaky gut is not itself a diagnosis. The claim traces to animal work examining intestinal barrier proteins and permeability — real research, and not a human result. Persistent digestive symptoms deserve a workup rather than a peptide, because celiac disease, inflammatory bowel disease, infection and several other findable causes produce them.

BPC-157 and gut health

Does BPC-157 help ulcerative colitis or Crohn's disease?

BPC-157 was studied as a drug candidate for inflammatory bowel disease and the program never reached approval, so it is not a treatment for either condition. Preclinical colitis models look favorable, and the human record amounts to one small early trial reported mostly in abstract. Ulcerative colitis and Crohn's disease have approved treatments with large trial evidence behind them, and delaying or stopping those in favor of a peptide carries a real risk of disease progression.

BPC-157 and gut health

Is TB-500 the same as thymosin beta-4?

No, and the difference matters whenever someone cites the evidence. Thymosin beta-4 is a naturally occurring protein that has been through human trials; TB-500 is a short synthetic peptide corresponding to part of that protein, and it is not the molecule those trials studied. Evidence gathered on thymosin beta-4 does not transfer to TB-500, and TB-500 is not FDA-approved.

Wolverine Stack

Why is it called the Wolverine Stack?

The Wolverine Stack is a nickname the peptide community gave to the pairing of BPC-157 and TB-500, after the comic-book character who heals from anything — marketing language rather than a clinical term. It sets an expectation neither compound has earned: neither is FDA-approved, and no human trial shows that either accelerates healing. A memorable name is not a finding.

Wolverine Stack

Is the Wolverine Stack better than BPC-157 alone?

No study has compared them — not in people, and not in animals with proper single-agent comparison arms — so the claim rests on mechanistic reasoning rather than on a result. TB-500 is studied for effects on cell migration and actin remodeling while BPC-157 is associated with blood supply and growth factor effects, which is a reason to hypothesize an additive effect, not a demonstration of one. Neither compound is FDA-approved, and combining two unproven things does not produce a proven one.

Wolverine Stack vs. BPC-157 alone

Is the Wolverine Stack FDA-approved?

No — neither BPC-157 nor TB-500 is an FDA-approved drug, and no approval exists for the combination. Both were among the twelve substances removed from Category 2 of the FDA's interim 503A list in April 2026 for procedural reasons, and both were recommended by an advisory committee in July 2026, but the rulemaking that would change their compounding standing had not completed as of September 2026. Compounded preparations are not FDA-approved and are not reviewed by the FDA for safety or effectiveness.

Wolverine Stack vs. BPC-157 alone

Is stacking peptides riskier than taking one?

Stacking adds unknowns and removes your ability to tell which substance caused any effect, good or bad — and with compounds that have no long-term human safety data, both of those weigh more than usual. If something improves you cannot say what improved it; if something goes wrong you cannot say what to stop. Where one pathway is clearly the issue, starting with one compound is the more informative choice.

Wolverine Stack vs. BPC-157 alone

What does KPV add to the Repair & Recovery Stack?

KPV is the anti-inflammatory component rather than a tissue-building one — a short fragment of alpha-melanocyte-stimulating hormone studied for effects on inflammatory signaling, where BPC-157 and TB-500 are studied for repair. The idea is that it addresses a different part of recovery than the other two, and no study has confirmed that it adds anything in a combination. KPV is not FDA-approved.

What KPV adds

How is the Repair & Recovery Stack different from the Wolverine Stack?

The Wolverine Stack is BPC-157 and TB-500; the Repair & Recovery Stack is those two plus KPV, which brings an anti-inflammatory angle the other two are not primarily studied for. Neither combination has been tested as a combination in humans, and none of the three components is FDA-approved. Adding a third compound adds a mechanism on paper and another unknown in practice.

Repair & Recovery Stack

Is there human evidence for KPV?

There is no published randomized controlled trial of KPV in humans, for any use. The KPV research base is preclinical and concentrated in mouse models of gut inflammation, where the findings are consistent enough to be interesting and are still not human results. KPV is not FDA-approved, and ACT 2 Health does not claim it treats any condition.

What KPV adds

Is KPV safe?

Long-term human safety data for KPV does not exist and short-term human data is essentially absent, so its safety is unstudied rather than established. That KPV is a fragment of a hormone the body already makes is reassuring in theory and is not evidence — origin says nothing about what a substance does when introduced from outside, or about what is in an unverified vial. KPV is not FDA-approved.

What KPV adds

Can KPV replace treatment for inflammatory bowel disease?

No. Inflammatory bowel disease has approved therapies supported by large trials, stopping them carries a real risk of disease progression, and KPV has no human trial evidence for any use. Any change to an inflammatory bowel disease regimen belongs with the specialist managing it rather than with a peptide prescription. KPV is not FDA-approved and is not a substitute for treatment of a diagnosed condition.

What KPV adds

What does DSIP stand for?

DSIP stands for delta sleep-inducing peptide, named in the 1970s after a substance isolated from rabbit brain appeared to increase delta-wave sleep in that experiment. The name describes what was hoped for rather than what has been demonstrated in people, which is a recurring problem across this category. DSIP is not FDA-approved for sleep or for anything else.

DSIP: the sleep evidence

Does DSIP actually improve deep sleep?

That has not been established in people. The name comes from an animal experiment, and the human work since has been small, old and inconclusive — some studies reported changes and others did not, and none of it amounts to evidence that DSIP treats a sleep problem. DSIP is not FDA-approved, and ACT 2 Health does not claim that it improves sleep.

DSIP: the sleep evidence

Is DSIP a sedative?

Not in the usual sense — DSIP does not act like a benzodiazepine or a so-called Z-drug, and there is no agreed mechanism by which it would produce sleep in a person. That is part of why the sleep claim is weak rather than merely unproven: the story has never been pinned down. DSIP is not FDA-approved, and a persistent sleep problem deserves a proper assessment rather than a substitute for one.

DSIP: the sleep evidence

Is DSIP safe?

There is no meaningful long-term human safety data for DSIP, which is different from knowing it is harmful and different from knowing it is safe. With the benefit side of the ledger this thin, an unknown on the risk side weighs more than it would for a compound that had something demonstrated to set against it. DSIP is not FDA-approved.

DSIP

Is DSIP legal?

DSIP is not an FDA-approved drug, and it is the one substance the FDA's Pharmacy Compounding Advisory Committee voted against recommending for the 503A Bulks List in July 2026 — it appears in that record under the name Emideltide. Material sold online as DSIP is typically labeled research use only, which is a laboratory chemical rather than a medicine. This describes regulatory status rather than offering legal advice.

DSIP: regulatory status

Is epithalon the same as epitalon?

Yes — epithalon and epitalon are two spellings of the same short synthetic peptide, and you will also see epithalone and Epitalon used for it. The inconsistency comes from transliteration out of Russian, where the compound originated. Epithalon is not FDA-approved under any spelling.

Epithalon

Does epithalon extend lifespan?

No evidence exists that would allow anyone to tell you it does, and ACT 2 Health will not. The lifespan claim traces to older rodent and observational work from a single research tradition, and no controlled human trial has shown an effect on lifespan or on any hard health outcome. Epithalon is not FDA-approved.

The epithalon telomere claim

Does epithalon lengthen telomeres in humans?

That has not been established. The telomere and telomerase findings behind the claim come from cell-culture experiments, mostly from a single Russian research group, and no controlled human trial has shown a corresponding clinical outcome. Changing an enzyme's activity in a dish is a laboratory observation rather than a demonstration that anything happens to a person's health.

The epithalon telomere claim

Is epithalon FDA-approved?

No. An FDA advisory committee recommended epithalon for the 503A compounding list in July 2026, but a recommendation is advice to the agency: formal addition requires notice-and-comment rulemaking, which had not completed as of September 2026. Epithalon is not an approved drug for any indication, and eligibility for pharmacy compounding would not make it one.

The epithalon telomere claim

Why is most epithalon research Russian?

Because the compound originated there. Epithalon grew out of work on epithalamin, a pineal gland extract studied at the St Petersburg Institute of Bioregulation and Gerontology, and most of the literature comes from that one program. Concentration in a single research tradition — rather than the country it happens to be in — is the reason the findings have not been independently replicated in the kind of trials Western regulators rely on.

Epithalon: the evidence

Is MOTS-c an exercise mimetic?

The phrase exercise mimetic comes from laboratory work on MOTS-c and oversells what has been shown in people. In cell and animal models MOTS-c activates pathways that exercise also activates, which is where the label came from; no human trial has shown that taking MOTS-c produces the effects of training. MOTS-c is not FDA-approved, and nothing in its evidence base is a reason to train less.

MOTS-c and exercise

Can I take MOTS-c instead of training?

No, and on the evidence alone it is a bad trade. Exercise has trial evidence for mortality, cardiovascular events, diabetes, falls and cognition; MOTS-c has animal work and a mechanism, and is not FDA-approved. The exercise-mimetic research that produced the phrase was aimed at people who physically cannot exercise, not at people who are short of time.

MOTS-c and exercise

Does MOTS-c improve insulin sensitivity?

MOTS-c has been reported to improve insulin sensitivity in mice. No controlled human trial has established that effect in people, so ACT 2 Health makes no such claim, and MOTS-c is not FDA-approved. Where insulin resistance is the actual problem, the steps with real evidence behind them are a metabolic panel, training, diet, and an approved medication where one is indicated.

MOTS-c: the metabolic evidence

Is MOTS-c like metformin?

Both MOTS-c and metformin are understood to activate AMPK, by different routes, and that is where the resemblance stops. Metformin has decades of trials and outcome data behind it; MOTS-c has neither and is not FDA-approved. The comparison describes a shared pathway rather than an equivalence, and treating it as an equivalence is exactly how a preclinical compound acquires a reputation it has not earned.

MOTS-c: the metabolic evidence

Does the July 2026 FDA committee vote mean MOTS-c works?

No. The Pharmacy Compounding Advisory Committee was considering eligibility for pharmacy compounding, not effectiveness, and it recommended MOTS-c on a narrow split with abstentions and against FDA staff's own recommendation. That recommendation still requires notice-and-comment rulemaking to take effect, and the rulemaking had not completed as of September 2026. MOTS-c is not FDA-approved, and a vote about compounding rules says nothing about whether a compound does anything.

MOTS-c: the metabolic evidence

Results vary. Clinical trial results apply only to the FDA-approved branded medication specifically identified and do not apply to compounded medications. All medications must be prescribed by a licensed provider based on medical necessity.